Skip to main content
x

Primary hyperoxaluria-mapping impact and gaining insights

In September, while attending the Annual 2019 Global Genes Patient Advocacy Summit in San Diego, our RARE Revolution team had the privilege of hosting a roundtable in partnership with Dicerna Pharmaceuticals and the Oxalosis and Hyperoxaluria Foundation (OHF). Rebecca, CEO of RARE Revolution recounts their individual stories and collective experiences. (Page 54-Page 58)

Outside Link
https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=71b9e7f9-862d-4804-93b9-97d4aeeeddc9&pnum=54

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.